Diagnosing MS

Most patients with probable MS will progress rapidly to definite MS.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

NEW YORK, Aug 1 (Praxis Press) A definite diagnosis of multiple sclerosis (MS) can only be reached after the second neurologic relapse occurs. Therefore, between the first and second relapse, patients are classified as having probable MS. To investigate the rate of progression from probable to clinically definite MS, Achiron and colleagues performed a 7-year prospective study of 163 patients experiencing their first episode of neurologic symptoms suggestive of MS. They found that within the follow-up period (mean, 42 months), 136 patients had an additional relapse and were therefore defined as having clinically definite MS, whereas 27 patients were defined as having clinically probable MS. The researchers also analyzed demographic and clinical parameters at presentation to identify variables predictive of rapid progression (within one year) to clinical definite MS. Motor involvement at onset was the only clinical parameter associated with rapid progression to a definite diagnosis. Polysymptomatic involvement and higher ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform